Venous Thromboembolism - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 86 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Venous Thromboembolism - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Venous Thromboembolism - Pipeline Review, H2 2014', provides an overview of the Venous Thromboembolism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Thromboembolism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Venous Thromboembolism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Thromboembolism Overview 7
Therapeutics Development 8
Pipeline Products for Venous Thromboembolism - Overview 8
Pipeline Products for Venous Thromboembolism - Comparative Analysis 9
Venous Thromboembolism - Therapeutics under Development by Companies 10
Venous Thromboembolism - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Venous Thromboembolism - Products under Development by Companies 15
Venous Thromboembolism - Companies Involved in Therapeutics Development 16
Sanofi 16
Isis Pharmaceuticals, Inc. 17
Daiichi Sankyo Company, Limited 18
Bayer AG 19
Portola Pharmaceuticals, Inc. 20
Green Cross Corporation 21
Regado Biosciences, Inc. 22
GlycoMimetics, Inc. 23
Gamma Therapeutics, Inc. 24
Venous Thromboembolism - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
edoxaban tosylate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rivaroxaban - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
semuloparin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
betrixaban - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rivaroxaban - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ISIS-FXIRx - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
REG-2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GCC-2107 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GMI-1271 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gammarin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Lysimab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Venous Thromboembolism - Recent Pipeline Updates 54
Venous Thromboembolism - Dormant Projects 71
Venous Thromboembolism - Discontinued Products 72
Venous Thromboembolism - Product Development Milestones 73
Featured News & Press Releases 73
Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 73
Aug 25, 2014: New Pradaxa data to be presented at the ESC Congress 2014 74
Jun 30, 2014: U.S. FDA grants Breakthrough Therapy Designation to Pradaxa (dabigatran etexilate) specific investigational antidote 75
Jun 20, 2014: Boehringer Ingelheim Initiates RE-CIRCUIT Trial, Evaluating Pradaxa (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation 76
Jun 11, 2014: Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin 77
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 78
May 22, 2014: Antidote for rapid reversal of Pradaxa progresses into next stage of clinical investigation with study in patients 79
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 79
May 15, 2014: As the benefits and safety of Pradaxa are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients 80
May 12, 2014: Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO 82
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
Number of Products under Development for Venous Thromboembolism, H2 2014 8
Number of Products under Development for Venous Thromboembolism - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Venous Thromboembolism - Pipeline by Sanofi, H2 2014 16
Venous Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 17
Venous Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 18
Venous Thromboembolism - Pipeline by Bayer AG, H2 2014 19
Venous Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 20
Venous Thromboembolism - Pipeline by Green Cross Corporation, H2 2014 21
Venous Thromboembolism - Pipeline by Regado Biosciences, Inc., H2 2014 22
Venous Thromboembolism - Pipeline by GlycoMimetics, Inc., H2 2014 23
Venous Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Venous Thromboembolism Therapeutics - Recent Pipeline Updates, H2 2014 54
Venous Thromboembolism - Dormant Projects, H2 2014 71
Venous Thromboembolism - Discontinued Products, H2 2014 72